Institute Of Hematology & Blood Diseases Hospital, China

This early-stage study is testing a one-time gene therapy injection called KL003 for people with severe sickle cell disease. The treatment involves collecting a patient's own blood stem cells, modifying them in a lab to produce healthy hemoglobin, and then returning them to the p…

This is a very early study to check the safety and first signs of effectiveness of a new type of CAR-T therapy called IASO206 for patients with multiple myeloma that has come back or stopped responding to standard treatments. The therapy is designed to be given directly into the …

This study looks back at medical records to see if an injection called Polyene Phosphatidylcholine helps prevent or treat liver injury in adults with blood cancers who are receiving chemotherapy. Researchers will analyze data from 1,000 patients to check if the drug improves live…

This early-stage study is testing a new type of treatment called IASO104, a CAR-T cell therapy, for people with multiple myeloma that has come back or stopped responding to other treatments. Doctors will give patients their own modified immune cells to try to fight the cancer. Th…

This study is testing whether personalized probiotic capsules made from a patient's or donor's own gut bacteria can help improve intestinal problems in people who develop acute graft-versus-host disease after a stem cell transplant. Researchers will enroll 10 patients over 50 yea…

This study is testing a combination of three drugs (zanubrutinib, bendamustine, and a CD20 antibody) for people newly diagnosed with a rare blood cancer called Waldenström macroglobulinemia (WM). The goal is to see how well this combination can achieve deep, lasting responses by …

This early-stage study is testing the safety and initial effectiveness of a new type of CAR-T cell therapy called CT1195E. It is for adults with B-cell non-Hodgkin lymphoma or acute lymphoblastic leukemia that has come back or not responded to standard treatments. Researchers wil…

This early-stage study is testing the safety and initial effectiveness of a new three-drug combination (called VAM) for adults newly diagnosed with acute myeloid leukemia (AML), a type of blood cancer. The study will enroll 30 participants who are eligible for strong chemotherapy…

This early-stage study is testing a new cell therapy called LVIVO-TaVec400 for people with multiple myeloma that has returned or stopped responding to standard treatments. The study will enroll about 38 adults who have already tried at least three other therapies. Researchers wil…

This study is testing whether adding the drug Gecacitinib before, during, and after a stem cell transplant can help people with myelofibrosis, a serious bone marrow disease. The main goal is to see if the drug helps patients survive the first year after transplant without their d…

This early-stage study is testing an experimental drug called Gecacitinib for people with chronic graft-versus-host disease (cGVHD) that doesn't improve with standard steroid treatment. The trial will first find a safe dose and then see if the drug helps control the disease and i…

This study is testing a new drug called zuberitamab to see if it can safely and effectively treat early signs of Epstein-Barr virus (EBV) infection in adults who have recently received a donor stem cell transplant. The goal is to prevent the virus from causing a serious, often fa…

This study is testing a new drug called CM336, a targeted antibody, as a maintenance therapy for people with newly diagnosed multiple myeloma who have had a stem cell transplant. The goal is to see if this drug can help eliminate any remaining traces of cancer cells and prevent t…

This early-stage study is testing the safety of a new cell therapy for people with severe autoimmune diseases that haven't responded to standard treatments. The therapy involves modifying immune cells to target specific markers on harmful B cells. Researchers will enroll 9 adults…

This study is testing a personalized scoring system to help doctors decide the safest time to stop preventive antiviral medication after a stem cell transplant. It aims to reduce the risk of a common and serious viral infection called CMV while avoiding the side effects of taking…

This early-stage study is testing whether a three-drug combination can effectively control Waldenström Macroglobulinemia when given for a fixed period instead of indefinitely. Researchers will first find the safest dose of one drug, then test that dose in more patients to see how…

This early-stage study is testing a new type of CAR-T cell therapy for adults with B-cell lymphoma that has come back or hasn't responded to standard treatments. The main goal is to find a safe dose and check for side effects. Researchers will also look for early signs that the t…

This study is testing whether a new combination of three targeted drugs works better than standard chemotherapy for adults with a specific genetic type of acute myeloid leukemia (AML). About 300 newly diagnosed patients with an FLT3 gene mutation will receive either the new drug …

This early-stage trial is testing a new cell therapy called JY509 for children and teenagers (ages 3-18) whose B-cell acute lymphoblastic leukemia has come back or hasn't responded to standard treatments. The study will give participants an injection of universal natural killer (…

This study is testing a new treatment approach for adults with a type of blood cancer called acute lymphoblastic leukemia (ALL). It combines a chemotherapy regimen designed for children with two newer types of drugs: venetoclax and immunotherapy. The goal is to see if this combin…

This is an early safety study testing a new cell therapy called SL4903 for adults with multiple myeloma that has come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to target the cancer, and infuse them b…

This study aims to find the best next-step treatment for ITP patients whose initial platelet-boosting medication didn't work. Researchers will compare switching to a double dose of the original drug (rhTPO) versus switching to a different medication (eltrombopag). The study will …

This study is testing a combination of two drugs, olverembatinib and inotuzumab ozogamicin, for adults with a specific type of acute leukemia (Ph+ ALL). The goal is to see if this treatment can clear very low levels of remaining cancer cells after initial chemotherapy, which is a…

This early-phase study is testing a new two-step treatment for adults with acute myeloid leukemia (AML) that has come back or hasn't responded to other therapies. Doctors will first give patients one type of engineered immune cell (CAR-T), then a second type, with the goal of con…

This early-phase study is testing a new type of CAR-T cell therapy for children and teenagers with high-risk T-cell leukemia or lymphoma. The goal is to see if collecting a patient's own immune cells, modifying them to target cancer, and reinfusing them can safely prevent the can…

This early-stage study is testing a new two-step approach for patients with multiple myeloma that has come back or stopped responding to many standard treatments. First, patients receive a special antibody drug (BCMA/CD3 bispecific antibody) to help prepare their body. Then, they…

This study is testing whether adding a new drug called a JAK1 inhibitor to standard immune-suppressing therapy can help people with severe aplastic anemia. The trial has two parts: first testing safety in patients whose disease hasn't responded to standard treatment, then testing…

This study is testing a new combination of two drugs, pomalidomide and obinutuzumab, for people with slow-growing (indolent) lymphoma that has returned or isn't responding to prior therapy. The first part finds the safest, most effective dose. The second part checks how well the …

This study is testing if metformin, a common diabetes medication, can reduce the level of a specific genetic mutation found in some patients with acute leukemia who are currently in remission. The goal is to see if lowering this mutation can help prevent the cancer from returning…

This study is testing a specific combination of chemotherapy drugs given before a cord blood transplant for patients aged 60-69 with blood cancers. The goal is to see if this new preparatory regimen is safe and effective at helping the transplant succeed while controlling the can…

This study aims to find out which initial treatment works better for severe aplastic anemia, a condition where the bone marrow stops making enough blood cells. It will compare a stem cell transplant from a partially matched family donor to a strong course of immune-suppressing me…

This early-stage study is testing a drug called daratumumab in adults with a severe form of aplastic anemia that has not responded to or has come back after standard treatments. The main goals are to find a safe dose and see if the drug can help improve patients' blood counts. Th…

This study is testing a new type of cell therapy called CD19 UCAR-T in people with various autoimmune diseases that haven't responded well to standard treatments. The main goals are to see if the treatment is safe and if it can help control the diseases. It will involve a small g…

This study is testing whether adding specific targeted drugs to standard chemotherapy works better for adults with a hard-to-treat type of leukemia called 'Ph-like ALL.' Doctors will give patients either olverembatinib or ruxolitinib based on their specific genetic test results, …

This study is testing whether a drug called luspatercept can help patients with blood cancers recover from anemia (low red blood cells) after a stem cell transplant. Researchers want to see if the drug reduces the need for blood transfusions and helps the new stem cells work bett…

This study tests whether using precise, high-dose radiation on tumors outside the bone marrow before a stem cell transplant improves outcomes for adults with blood cancers. It aims to see if this approach helps patients live longer and reduces the chance of the cancer returning. …

This early-phase study is testing a new two-step approach for patients with multiple myeloma that has come back or stopped responding to many standard drugs. First, patients receive an antibody drug (QLS32015) that helps the immune system target cancer cells. This is followed by …

This is an early-stage study to test the safety and find the right dose of an experimental cell therapy called CT1390B. It will enroll up to 18 adults whose acute myeloid leukemia has come back or hasn't responded to standard treatments. The main goal is to see if the treatment i…

This study is testing a new, less toxic combination of chemotherapy drugs (thiotepa and melphalan) for patients with an aggressive form of chronic myeloid leukemia (CML) called blast phase. The goal is to better control the disease and improve survival by preparing patients for a…

This study is testing if adding a vitamin A-related drug (all-trans retinoic acid) to a standard platelet-boosting drug (avatrombopag) works better for controlling immune thrombocytopenia (ITP) than the standard drug alone. It will involve about 248 adults whose ITP did not fully…

This study is testing a new combination treatment for adults with a rare and aggressive type of leukemia that is difficult to classify and treat. The treatment combines a targeted immunotherapy drug (blinatumomab), a standard chemotherapy approach, and two other newer drugs (vene…

This early-stage study is testing a new type of CAR-T cell therapy for adults with large B-cell lymphoma that has come back or not responded to standard treatments. The main goals are to check the safety of the treatment and see if it helps shrink tumors. Only three participants …

This is an early, small study to test the safety and initial effects of a new cell therapy called GC012F for people with difficult-to-treat rheumatoid arthritis (RA). It will enroll 9 adults whose RA has not responded well to multiple standard treatments. Researchers will give pa…

This is an early-stage study to test the safety and find the right dose of a new CAR-T cell therapy called CT1194D. It is for adults with B-cell blood cancers, like certain lymphomas and leukemias, that have come back or not responded to standard treatments. Researchers will also…

This study is testing a combination of three medications (obinutuzumab, zanubrutinib, and lenalidomide) as the first treatment for adults with mantle cell lymphoma, a rare blood cancer. All 37 participants will receive the initial drug combination, then maintenance therapy tailor…

This study is testing an existing drug, daratumumab, for adults with a hard-to-treat type of leukemia called T-ALL. It's for patients who have responded to standard chemotherapy but still have tiny amounts of cancer cells left, which raises the risk of the disease coming back. Th…

This study is testing a new combination of three targeted drugs (zanubrutinib, obinutuzumab, and lenalidomide) for people with follicular lymphoma who haven't had any previous treatment. The goal is to see if this chemotherapy-free approach can effectively control the cancer whil…

This early-stage study tests whether special immune cells from a stem cell donor can prevent Epstein-Barr virus (EBV) infection in transplant patients. Researchers will give these donor-derived cells to 9-18 patients who are at high risk for EBV infection after their transplant. …

This study is testing whether a drug called ivarmacitinib can prevent acute graft-versus-host disease (aGVHD) in people with blood cancers who receive stem cell transplants from partially matched donors. The trial will enroll 32 patients to see how well the drug prevents moderate…

This study aims to understand how immune thrombocytopenia (ITP), a condition causing low platelet counts, is currently treated in China. Researchers will look back at the medical records of 500 patients to see what treatments doctors chose and how well those treatments worked. Th…

This study aims to understand how often dangerous antibiotic-resistant bacteria appear in stem cell transplant patients and how frequently these bacteria lead to serious infections. Researchers will follow 1,000 adult patients after their transplants, checking for bacteria throug…